Inclusion body myositis is a form of inflammatory myopathy. We identified 4 cases of inclusion body myositis showing granuloma formation in muscle tissue and aimed to assess the features of this atypical form of the inclusion body myositis. 
Introduction
Inclusion body myositis (IBM) is a type of inflammatory myopathy characterized by T lymphocyte infiltration around muscle fibers and the presence of rimmed vacuoles [1] .
In comparison to other types of inflammatory myopathy, including polymyositis and dermatomyositis, patients with IBM demonstrate an unfavorable response to immunosuppressive therapy [1] . The pathomechanisms of IBM remain uncertain.
Inflammatory processes and degenerative mechanisms are both responsible for the development of this muscular disorder.
Granulomas are pathological structures comprising giant cells, macrophage-like epithelioid cells, and lymphocytes. The most common condition associated with non-caseating granuloma formation in muscle tissues is sarcoidosis Sakai 6 followed by foreign-body reactions and infectious conditions; however, granulomatous myositis (GM) is a type of inflammatory myopathy containing granulomas without any evidence of systemic sarcoidosis despite intensive clinical investigations [2] .
Although there are several reported cases that presented features of both IBM and sarcoidosis [3] [4] [5] , the relationship between IBM and granuloma formation remains to be clarified. In this study, we identified 4 patients with IBM showing granuloma formation in muscle tissues. Somewhat surprisingly, granulomas were confined to skeletal muscle in 3 patients. This study aimed to elucidate the features of IBM with granuloma by comparing these features with the clinical and histopathological features of patients with typical IBM.
Materials and methods

Patients
We retrospectively reviewed consecutive patients who underwent an open muscle biopsy in our hospital and were referred to our department for pathological diagnosis of muscle biopsies between 2003 and 2013. We selected IBM patients who satisfied Sakai 7 the European Neuromuscular Centre (ENMC) IBM Research Diagnostic Criteria 2011 [6] , and applied the classification as follows: clinicopathologically defined IBM, clinically defined IBM, and probable IBM.
Medical records were retrospectively reviewed for age at diagnosis, sex, sites of initial weakness, and duration from onset to diagnosis. The following laboratory features determined at the time of diagnosis were obtained: the levels of serum creatine kinase, lactate dehydrogenase, aldolase, and myoglobin; levels of plasma C-reactive protein; and erythrocyte sedimentation rate. In addition, we examined the presence of serum autoantibodies suggestive of other collagen disorders, hepatitis B antigens, and hepatitis C antibodies.
Special attention was paid to patients showing granulomas in muscle to exclude the possibility of systemic sarcoidosis. A clinical diagnosis of sarcoidosis could be made on the basis of clinical, laboratory, and radiological features in addition to evidence of non-caseating granulomas in tissues. Moreover, it is essential to exclude alternative diseases [7] . In terms of clinical presentation, pulmonary symptoms and abnormal chest radiographs including bilateral hilar lymphadenopathy are common; however, rarely patients may show only extrapulmonary manifestations Sakai 8 [7. ] Granulomatous myositis is a type of myositis characterized by granuloma formation in muscle tissue, variable response to immunosuppressive therapies, and no evidence of systemic sarcoidosis [2] . Although it is uncertain whether GM is a limited form of systemic sarcoidosis, not all patients with GM develop symptoms of sarcoidosis [8] . To avoid making a diagnosis of sarcoidosis, the patients with IBM showing granuloma underwent intensive examinations, which included ophthalmological examinations, chest radiographs, and whole body examinations.
Other disorders which might cause granulomatous myositis, such as tuberculosis infection, lymphoma, intestinal inflammatory disease, myasthenia gravis, foreign-body reaction, cryofibrinogenemia, and primary biliary cirrhosis [2] , were excluded carefully by performing radiological and clinical investigations.
Most patients received immunosuppressive therapy as follows:
corticosteroids (prednisone and methylpredonisolone), immunosuppressive drugs, and intravenous immunoglobulin (IVIg). The results of these treatments were examined by retrospectively reviewing the medical records.
Written informed consent to participate in this study was obtained from the patients. The study protocol was approved by the medical ethics committee of Sakai 9 Kanazawa University.
Pathological examinations
Muscle biopsies were performed in all patients. All samples were obtained by open biopsies and divided into several blocks. Some specimens were immediately frozen in isopentane cooled with liquid nitrogen and stored at -80˚C until the experiments.
Serial 6-µm-thick cryostat sections were cut and stained with hematoxylin and eosin (HE), modified Gomori trichrome, NADH-tetrazolium, Congo Red, and cytochrome C oxidase (COX). The remaining samples were fixed with 10% buffered formalin.
Pathological examinations were also performed on 5-µm-thick sections of paraffin embedded blocks using HE and Congo Red. The EnVision system (Dako) was used for these immunolabeling studies. Peroxidase labeling was visualized with diaminobenzidine as the chromogen.
Granulomas were defined as collections of inflammatory cells in which more than 60% of the inflammatory cells were macrophages or epithelioid histiocytic cells, as judged by HE or specific macrophage marker staining (CD68). The presence of Langerhans-type or histiocytic giant cells was unnecessary to be judged as granulomas [9] . We paid special attention to exclude necrotic regions to avoid including caseating granulomas [9] .
Case classification
With reference to the pathological features of IBM (endomysial inflammatory infiltrates; rimmed vacuoles; protein accumulation; and upregulation of HLA class I around muscle fibers), we made a clinicopathological diagnosis of IBM [6] . Patients who demonstrated only these features were designated as typical IBM without granuloma group. Patients showing granuloma formation in addition to typical IBM Sakai 11 clinicopathologic characteristics were categorized into the IBM with granuloma group.
Statistical analysis
Differences in age at disease onset and in the results of laboratory tests between the typical IBM without granuloma group and the IBM with granuloma group were assessed using a Mann-Whitney U test. Sex, diagnosis classification of IBM, initial weakness, and pathological findings were assessed using chi-square test and Fisher's exact probability test. Statistical significance was defined as p < 0.05. Statistical analyses were performed using SPSS version 22 (IBM, Armonk, NY).
Results
Clinical profiles
A total of 307 patients with myopathy were analyzed in our department during the study period. Fifteen patients satisfied the clinical diagnostic criteria of IBM [6] . Five patients were categorized as clinicopathologically defined IBM. Four and 6 patients were categorized as clinically defined IBM and probable IBM, respectively.
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Granuloma formation in muscle tissues was noted in 4 patients. In these patients, one patient met the criteria for clinicopathologically defined IBM, whereas 2 and 1 patients were categorized as clinically defined IBM and probable IBM, respectively.
Regarding IBM patients with granuloma, clinical features are summarized in Table 1 Table 2 . There were no significant differences regarding the clinical profile between these groups. Several patients in the typical IBM without granuloma group were also positive for anti-nuclear antibody, anti-mitochondrial antibody, anti Ro/SS-A antibody, and exhibited a combined infection with hepatitis B virus and hepatitis C virus. Although patients with typical IBM received immunomodulating treatments, such as oral prednisone, IVIg, and immunosuppressants, all patients showed progression of muscular weakness regardless of the treatments administered.
Additionally, 2 patients were observed but were not treated apart from physical rehabilitation and exhibited slowly progressive muscular weakness.
Pathological findings
The quadriceps femoris muscle was the most frequently biopsied muscle in this series; (Figs 2C-F) [10] . As regards the myopathological findings except for the presence of granuloma, there were no significant differences between the two groups ( Table 3 ).
Discussion
We identified IBM with granuloma formation in the muscle tissues of 4 (27%) of 15 consecutive patients who underwent muscle examinations. All patients met current Sakai 15 clinocopathological diagnostic criteria for IBM [6, 11] . Although mediastinal lymph node granulomas were histologically demonstrated in patient 3, other patients demonstrated granuloma formation confined to muscle tissues as determined by intensive examinations. Hence, no patients received a diagnosis of sarcoidosis because of inadequate evidence.
Granulomas are structures associated with reaction to a foreign environment [2] . There are several reports of patients with GM showing the following features: myositis with granuloma, no evidence of sarcoidosis, and a good response to immunotherapy [2, 9] . Somewhat interestingly, some GM patients mimicked IBM in clinical characteristics; however, these cases showed no pathological features consistent with IBM, such as rimmed vacuole, amyloid deposition or abnormal protein accumulation in muscle fiber [12] . In a large muscle biopsy series, 12 cases (0.4%) of 2985 specimens were identified as having granulomatous inflammation [8] . It is well known that some patients with sarcoidosis demonstrate asymptomatic granuloma formation in muscle; however, microscopic criteria for the differentiation of sarcoid lesions from other granulomatous myopathies are still lacking [10] . The relationship between GM and the limited lesions of sarcoidosis in muscle remains unknown.
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It is uncertain whether granuloma formation in patients with the typical clinicopathologic characteristics of IBM is a coincidence or not. There are several case reports showing a combination of sarcoidosis and IBM [3, 5] . Clinical manifestations related to sarcoidosis preceded IBM in all reported cases. The authors of the above mentioned cases assumed that sarcoidosis was responsible for inducing IBM under uncertain circumstances [3, 5] . We presume that IBM and granuloma might share a similar pathogenesis on account of the following reasons. Firstly, our cases of IBM with granuloma formation were indistinguishable from typical IBM in terms of the clinicopathologic profiles, including clinical manifestations, pathological findings, and an unfavorable response to therapy (Tables 2 and 3 ), suggesting that IBM with granuloma could be a form of IBM. Secondly, inflammatory and degenerative mechanisms in IBM closely interrelate with each other [13] . A mouse model of IBM showing augmenting amyloid β protein in skeletal muscle demonstrated inclusion bodies and inflammatory infiltrates [14] . Abnormal protein accumulation in muscle fiber is a typical pathological feature of IBM patients. Deposited proteins acknowledged as foreign bodies against immune systems might develop granuloma formation. Finally, IBM and granuloma could share the same pathomechanistic Sakai 17 background. Sarcoidosis and IBM are Th1-mediated immune diseases [7, 15] .
Toll-like receptors (TLRs) are pattern-recognition receptors of the innate immune system that recognize conserved microbial motifs [16] , and are involved in autophagy [17] . Mechanisms involving autophagy dysregulation are observed in IBM [18] .
TLRs are also associated with inflammation in idiopathic inflammatory myopathies including IBM [16, 18] . Toll-like receptor 2 (TLR2), a member of the TLR family, is associated with activation of granulomatous inflammation in sarcoidosis [19] .
Furthermore, autophagy-related genes may contribute to granuloma formation [20] . 
